Save up -80% on Insulin Glargine

Note: this is a drug discount program, not an insurance plan.
RX BIN: 015558RX PCN: HTGroup ID: DDN6600Card Holder ID: DDN6600
Pharmacists and Patients support.

2019 Price of Lantus

$2721 carton (5 solostar pens) 3ml
Price with discount in nearest pharmacy. Price may vary.

Claim your free Insulin Glargine discount card

We offer free Lantus coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Insulin Glargine every time. What are you waiting for? Claim your prescription drug card now!

Walgreens pharmacy
Walgreens pharmacy
CVS pharmacy
CVS pharmacy
Walmart pharmacy
Walmart pharmacy
Ride AID pharmacy
Ride AID pharmacy
CVS Target pharmacy
CVS Target pharmacy
Kroger pharmacy
Kroger pharmacy

Get your Prescription


It’s safe and free


Buy drugs in pharmacy

save money

Save money each time

Insulin Glargine volume of distribution

AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.
RX Prescription
Ask Your therapeut before taking any drugs.

About RX24Drugs

2018 Statistics

discount card

Discount Cards 16,000+


Clients Benefit 29%


Total savings $4,735,080

What is Insulin Glargine

Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.

Insulin Glargine mechanism of action

Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.

Dosage forms of Insulin Glargine

Lantus SoloStar 100 unit/ml Solution 1 Box = Five 3ml Syringes$223.89box
Lantus 100 unit/ml Solution 10ml Vial$111.88vial
Lantus for OptiClik 100 unit/ml Solution 3ml Cartridge$44.78cartridge
Lantus 100 unit/ml cartridge$14.35ml
Lantus solostar 100 unit/ml$14.35ml

Prescription Generics


International Brands

Basaglar, Lantus, Lantus SoloStar, Toujeo


Insulin Glargine (rDNA origin) Insulin glargine recombinant


Eli Lilly Canada Inc

CAS number






Affected organisms

Humans and other mammals

Indication of Insulin Glargine

For the treatment of Type 1 or 2 diabetes mellitus in patients over 17 years old who require a long-acting (basal) insulin for the control of hyperglycemia. May be used in pediatric patients with Type 1 diabetes mellitus who require a long-acting (basal) insulin for glycemic control.

Toxicity of Insulin Glargine

Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Other adverse events that may occur include allergic reaction, injection site reaction, lipodystrophy, pruritis, and rash.

RX24 Drugs Disclaimer: consult your healthcare provider before buying a Insulin Glargine on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Insulin Glargine now!

What is Lantus?

Lantus is the first true basal analogue of human insulin, which provides a fairly flat insulinemic curve for 20-24 hours. Currently, it is one of the most frequently prescribed drugs of prolonged action in the world diabetological practice.

A distinctive feature of the drug is the high predictability of the rate of its absorption from the subcutaneous depot. In the subcutaneous fat, Lantus is in crystalline form. After subcutaneous injection, the insulin crystals slowly dissolve and free insulin gradually flows from the depot to the blood. If we compare the modern ideology of modifying the rate of insulin absorption realized in the creation of ultrashort and prolonged insulin, the principle turns out to be a mirror.

Ultra-short-acting drugs have been obtained as a result of blocking the natural process of formation of insulin crystals (hexamers), and long-acting, on the contrary, by stimulating the formation of such insulin crystals, from which insulin enters the blood very slowly.

Insulin Lantus is administered once a day. Although it was shown that the administration of the drug in the morning gives the same hypoglycemic effect as the evening administration, however, in some patients it lasts less than 24 hours and therefore, after the morning injection of Lantus, they cannot control lean toglycemia. In this case, the introduction of the drug is more justified in the evening. Lantus is usually marketed as a drug for starting insulin therapy for diabetes mellitus in combination with non-insulin hypoglycemic drugs when they are not effective enough.

It is also recommended for treatment in the “basis-bolus” mode, that is, in combination with ultrashort / short-acting drugs. In a patient who has not previously received insulin preparations, the initial dose of Lantus is 10 units/day. If the patient is transferred from a prolonged preparation of NPH insulin to Lantus, then the daily dose of Lantus should be 20% less than the dose of NPH insulin. The drug is administered subcutaneously and is not intended for intravenous administration. Concentration 100 units/ml. It is recommended to appoint children aged 6 years and older.

What is Toujeo?

Toujeo is an anthropogenic form of a hormone produced in the body. Insulin is a hormone that works by lowering the level of glucose (sugar) in the blood. Insulin glargine is a long-acting insulin that starts working several hours after the injection and works evenly for 24 hours.

Toujeo SoloStar injection pen is used to improve blood sugar control in adults and children with diabetes. Some brands of this medication are for adults only. Carefully follow all instructions for the brand of insulin glargine you use.

Toujeo is used to treat type 2 diabetes in adults. Toujeo is also used to treat type 1 diabetes in adults and children who are at least 6 years old.

Toujeo SoloStar contains 3 times more insulin per milliliter (ml) as normal insulin. You should not use Toujeo if you have an episode of hypoglycemia (low blood sugar), or if you are in a state of diabetic ketoacidosis. Never use the handle of the Toujeo SoloStar injector with another person, even if the needle has been changed.

Toujeo is only part of a complete treatment program, which may also include diet, exercise, weight control, foot care, eye care, tooth care, and blood sugar testing. Watch your diet, medications and exercises very carefully. Changes in any of these factors may affect blood sugar levels.